

## **Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-based Cohort Study**

Dominik Menges, MD MPH<sup>1</sup> \*, Tala Ballouz, MD MPH<sup>1</sup> \*, Alexia Anagnostopoulos, MD MPH<sup>1</sup>,  
Hélène E Aschmann, PhD<sup>1</sup>, Anja Domenghino, MD<sup>1,2</sup>, Jan S Fehr, MD<sup>1</sup>, Milo A Puhan, MD  
PhD<sup>1</sup>

*<sup>1</sup> Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland*

*<sup>2</sup> Department of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich,  
University of Zurich, Switzerland*

\* These authors contributed equally to this work.

---

**Supplementary Material**

---

**Table S1:** Results from univariable and multivariable logistic regression models for the outcome of not having fully recovered at six to eight months after diagnosis.

Variable	N	Univariable			Multivariable <sup>a</sup>		
		OR	95% CI	p-value	OR	95% CI	p-value
<b>Age group (years)</b>	385						
18-39		—	—		—	—	
40-64		1.96	1.20 to 3.25	0.008	1.59	0.93 to 2.73	0.093
≥65		1.45	0.70 to 2.95	0.31	0.97	0.41 to 2.20	0.94
<b>Sex</b>	385						
Female		—	—		—	—	
Male		0.59	0.38 to 0.92	0.02	0.53	0.33 to 0.85	0.009
<b>Time since diagnosis (days)</b>	385	1.00	0.99 to 1.00	0.69	0.99	0.99 to 1.00	0.10
<b>Initial symptom severity</b>	385						
Mild to moderate		—	—		—	—	
Severe to very severe		2.5	1.60 to 3.94	<0.001	2.05	1.27 to 3.34	0.003
<b>Initial hospitalization</b>	385						
No		—	—		—	—	
Yes		1.75	1.03 to 2.96	0.038	1.17	0.63 to 2.16	0.61
<b>Initial ICU stay</b>	385						
No		—	—		—	—	
Yes		1.06	0.23 to 3.89	0.93	0.55	0.10 to 2.49	0.45
<b>Smoking status</b>	382						
Non-smoker		—	—		—	—	
Ex-smoker		1.44	0.88 to 2.36	0.15	1.48	0.87 to 2.52	0.14
Smoker		1.21	0.61 to 2.32	0.56	1.61	0.78 to 3.24	0.19
<b>Body mass index</b>	379	1.07	1.02 to 1.12	0.004	1.04	0.99 to 1.09	0.15
<b>Comorbidities</b>	384						
No		—	—		—	—	
Yes		2.21	1.40 to 3.48	<0.001	2.08	1.24 to 3.50	0.005

*Legend:* OR = Odds Ratio, CI = Confidence Interval, ICU = Intensive Care Unit; <sup>a</sup> adjusted for age group, sex, initial hospitalization, symptom severity, and comorbidities.

**Table S2:** Results from univariable and multivariable logistic regression models for the outcome of fatigue at six to eight months after diagnosis.

Variable	N	Univariable			Multivariable <sup>a</sup>		
		OR	95% CI	p-value	OR	95% CI	p-value
<b>Age group (years)</b>	426						
18-39		—	—		—	—	
40-64		0.58	0.38 to 0.89	0.012	0.59	0.39 to 0.91	0.018
≥65		0.4	0.21 to 0.73	0.003	0.41	0.21 to 0.78	0.007
<b>Sex</b>	426						
Female		—	—		—	—	
Male		0.69	0.47 to 1.02	0.062	0.72	0.49 to 1.07	0.10
<b>Time since diagnosis (days)</b>	426	1.00	1.00 to 1.01	0.85	1.00	1.00 to 1.01	0.52
<b>Initial symptom severity</b>	426						
Asymptomatic		—	—		—	—	
Mild to moderate		0.99	0.52 to 1.86	0.96	0.96	0.50 to 1.83	0.89
Severe to very severe		1.34	0.69 to 2.59	0.38	1.38	0.69 to 2.73	0.36
<b>Initial hospitalization</b>	426						
No		—	—		—	—	
Yes		0.77	0.47 to 1.26	0.30	1.00	0.59 to 1.71	0.99
<b>Initial ICU stay</b>	426						
No		—	—		—	—	
Yes		2.96	0.71 to 20.0	0.18	4.63	1.02 to 32.9	0.07
<b>Smoking status</b>	424						
Non-smoker		—	—		—	—	
Ex-smoker		1.35	0.87 to 2.11	0.18	1.58	1.00 to 2.52	0.05
Smoker		1.47	0.83 to 2.63	0.19	1.27	0.71 to 2.31	0.42
<b>Body mass index</b>	419	1.01	0.97 to 1.05	0.52	1.04	1.00 to 1.09	0.08
<b>Comorbidities</b>	426						
No		—	—		—	—	
Yes		0.91	0.61 to 1.36	0.65	1.27	0.81 to 2.01	0.30

*Legend:* OR = Odds Ratio, CI = Confidence Interval, ICU = Intensive Care Unit; <sup>a</sup> adjusted for age group, sex, and initial hospitalization.

**Table S3:** Results from univariable and multivariable logistic regression models for the outcome of mMRC dyspnea grade  $\geq 1$  at six to eight months after diagnosis.

Variable	N	Univariable			Multivariable <sup>a</sup>		
		OR	95% CI	p-value	OR	95% CI	p-value
<b>Age group (years)</b>	395						
18-39		—	—		—		
40-64		1.61	0.96 to 2.76	0.077	0.79	0.41 to 1.49	0.46
$\geq 65$		2.88	1.45 to 5.73	0.002	0.90	0.37 to 2.16	0.82
<b>Sex</b>	395						
Female		—	—		—		
Male		0.59	0.37 to 0.94	0.029	0.45	0.26 to 0.76	0.003
<b>Time since diagnosis (days)</b>	395	1.00	0.99 to 1.01	0.74	1.00	0.99 to 1.01	0.92
<b>Initial symptom severity</b>	395						
Asymptomatic		—	—		—		
Mild to moderate		0.87	0.40 to 2.07	0.74	1.00	0.40 to 2.73	>0.99
Severe to very severe		1.93	0.89 to 4.54	0.11	1.42	0.57 to 3.87	0.47
<b>Initial hospitalization</b>	395						
No		—	—		—		
Yes		4.06	2.39 to 6.91	<0.001	4.17	2.23 to 7.91	<0.001
<b>Initial ICU stay</b>	395						
No		—	—		—		
Yes		4.05	1.05 to 16.7	0.04	1.05	0.22 to 5.31	0.95
<b>Smoking status</b>	393						
Non-smoker		—	—		—		
Ex-smoker		1.62	0.97 to 2.69	0.06	1.66	0.92 to 3.00	0.093
Smoker		0.88	0.41 to 1.78	0.73	1.31	0.57 to 2.85	0.51
<b>Body mass index</b>	388	1.13	1.08 to 1.20	<0.001	1.14	1.08 to 1.20	<0.001
<b>Respiratory condition</b>	388						
No		—	—		—		
Yes		2.36	1.10 to 4.95	0.024	1.71	0.70 to 4.01	0.22
<b>Comorbidities</b>	395						
No		—	—		—		
Yes		3.93	2.44 to 6.40	<0.001	2.71	1.38 to 5.36	0.004

*Legend:* OR = Odds Ratio, CI = Confidence Interval, ICU = Intensive Care Unit; <sup>a</sup> adjusted for age group, sex, initial hospitalization, smoking, respiratory comorbidity, and body mass index.


**Table S4:** Results from univariable and multivariable logistic regression models for the outcome of depression at six to eight months after diagnosis.

Variable	N	Univariable			Multivariable <sup>a</sup>		
		OR	95% CI	p-value	OR	95% CI	p-value
<b>Age group (years)</b>	428						
18-39		—	—		—	—	
40-64		1.05	0.66 to 1.69	0.83	0.97	0.59 to 1.59	0.91
≥65		1.19	0.60 to 2.28	0.61	1.18	0.56 to 2.42	0.65
<b>Sex</b>	428						
Female		—	—		—	—	
Male		0.70	0.45 to 1.08	0.11	0.74	0.47 to 1.15	0.18
<b>Time since diagnosis (days)</b>	428	1.00	0.99 to 1.00	0.65	1.00	0.99 to 1.00	0.28
<b>Initial symptom severity</b>	428						
Asymptomatic		—	—		—	—	
Mild to moderate		0.84	0.40 to 1.92	0.67	0.85	0.40 to 1.94	0.69
Severe to very severe		2.08	0.99 to 4.71	0.062	2.05	0.96 to 4.69	0.074
<b>Initial hospitalization</b>	428						
No		—	—		—	—	
Yes		1.42	0.82 to 2.39	0.20	1.05	0.57 to 1.89	0.88
<b>Initial ICU stay</b>	428						
No		—	—		—	—	
Yes		0.81	0.12 to 3.42	0.80	0.47	0.07 to 2.17	0.37
<b>Smoking status</b>	426						
Non-smoker		—	—		—	—	
Ex-smoker		1.18	0.72 to 1.94	0.51	1.21	0.72 to 2.01	0.48
Smoker		1.56	0.83 to 2.84	0.16	1.71	0.89 to 3.21	0.10
<b>Body mass index</b>	421	1.02	0.98 to 1.06	0.40	1.02	0.97 to 1.06	0.51
<b>Comorbidities</b>	428						
No		—	—		—	—	
Yes		1.48	0.94 to 2.31	0.086	1.41	0.84 to 2.34	0.19
<b>Education</b>	426						
None or mandatory school		—	—		—	—	
Vocational training or specialized baccalaureate		0.34	0.13 to 0.90	0.028	0.31	0.11 to 0.85	0.022
Higher technical school or college		0.28	0.10 to 0.76	0.013	0.27	0.09 to 0.79	0.016
University		0.25	0.09 to 0.68	0.006	0.23	0.08 to 0.65	0.006
<b>Employment</b>	424						
Employed		—	—		—	—	
Student		0.53	0.08 to 2.01	0.42	0.6	0.09 to 2.41	0.53

Retired		1.41	0.76 to 2.54	0.26	1.89	0.58 to 6.11	0.28
Unemployed or other		2.60	1.18 to 5.64	0.016	2.53	1.12 to 5.63	0.023
<b>Income</b>	<b>405</b>						
<6'000 CHF		—	—		—	—	
6'000 - 12'000 CHF		0.91	0.54 to 1.53	0.72	1.05	0.61 to 1.81	0.87
>12'000 CHF		0.71	0.39 to 1.25	0.24	0.84	0.45 to 1.55	0.57

*Legend: OR = Odds Ratio, CI = Confidence Interval, ICU = Intensive Care Unit; <sup>a</sup> adjusted for age group, sex, initial hospitalization, and initial symptom severity.*

**Figure S1:** Venn diagram of the overlap of participants that have not fully recovered or are experiencing fatigue, dyspnea or depression at six to eight months after SARS-CoV-2 infection (total N=296).



**Table S5:** Overlap of participants not having recovered or experiencing fatigue, dyspnea, or depression and healthcare use at six to eight months after diagnosis.

Variable	Healthcare use related to COVID-19 <sup>a,b</sup>		Overall, N=431
	No, N=251	Yes, N=170	
<b>Recovery</b>			
Recovered to normal health status	214 (68.8%)	97 (31.2%)	320 (74.2%)
Not recovered to normal health status	37 (33.6%)	73 (66.4%)	111 (25.8%)
<b>Fatigue (measured by FAS)</b>			
No	121 (64.0%)	68 (36.0%)	193 (45.3%)
Yes	128 (56.1%)	100 (43.9%)	233 (54.7%)
Missing	2	2	5
<b>Dyspnea (measured by mMRC scale)</b>			
mMRC grade 0	196 (67.4%)	95 (32.6%)	299 (75.7%)
mMRC grade ≥1	36 (37.9%)	59 (62.1%)	96 (24.3%)
Missing	19	16	36
<b>Depression (measured by DASS-21)</b>			
No	203 (65.3%)	108 (34.7%)	317 (74.1%)
Yes	48 (44.4%)	60 (55.6%)	111 (25.9%)
Missing	0	2	3

*Legend:* FAS = Fatigue Assessment Scale, mMRC = modified Medical Research Council, DASS-21 = Depression, Anxiety and Stress Score (21 items). <sup>a</sup> Data on healthcare use missing from 10 individuals, <sup>b</sup> row percentages presented.



**Table S6:** Results from univariable and multivariable logistic regression models for the outcome of having at least one further healthcare contact (defined as rehospitalization, general practitioner visit or medical hotline call) related to COVID-19 within six to eight months after diagnosis.

Variable	N	Univariable			Multivariable <sup>a</sup>		
		OR	95% CI	p-value	OR	95% CI	p-value
<b>Age group (years)</b>	421						
18-39		—	—		—		
40-64		2.24	1.44 to 3.50	<0.001	1.94	1.22 to 3.10	0.005
≥65		3.18	1.73 to 5.92	<0.001	2.23	1.12 to 4.45	0.022
<b>Sex</b>	421						
Female		—	—		—		
Male		0.67	0.45 to 0.99	0.047	0.62	0.41 to 0.95	0.03
<b>Time since diagnosis (days)</b>	421	1.00	1.00 to 1.01	0.74	1.00	0.99 to 1.00	0.26
<b>Initial symptom severity</b>	421						
Asymptomatic		—	—		—		
Mild to moderate		1.46	0.72 to 3.19	0.31	1.50	0.72 to 3.34	0.30
Severe to very severe		3.38	1.64 to 7.45	0.002	2.59	1.21 to 5.87	0.018
<b>Initial hospitalization</b>	421						
No		—	—		—		
Yes		4.21	2.52 to 7.21	<0.001	2.94	1.66 to 5.32	<0.001
<b>Initial ICU stay</b>	421						
No		—	—		—		
Yes		14	2.59 to 259	0.013	3.65	0.61 to 70.1	0.24
<b>Recovery</b>	421						
Recovered to normal health status		—	—		—		
Not recovered to normal health status		4	2.76 to 6.97	<0.001	3.53	2.14 to 5.86	<0.001
<b>Fatigue</b>	417						
No		—	—		—		
Yes		1	0.94 to 2.07	0.1	1.61	1.04 to 2.50	0.032
<b>Dyspnea</b>	417						
mMRC grade 0		—	—		—		
mMRC grade ≥1		1	0.94 to 2.07	0.1	2.35	1.40 to 3.99	0.001
<b>Depression</b>	419						
No		—	—		—		
Yes		2	1.51 to 3.68	<0.001	2.13	1.32 to 3.45	0.002
<b>Smoking status</b>	418						
Non-smoker		—	—		—		

Ex-smoker		1.23	0.79 to 1.91	0.36	1.14	0.70 to 1.84	0.59
Smoker		0.86	0.47 to 1.54	0.61	1.16	0.61 to 2.18	0.64
<b>Body mass index</b>	413	1.01	0.98 to 1.05	0.48	0.99	0.94 to 1.03	0.57
<b>Comorbidities</b>	420						
No		—	—		—	—	
Yes		1.80	1.20 to 2.72	0.005	1.14	0.70 to 1.84	0.59

*Legend: OR = Odds Ratio, CI = Confidence Interval, ICU = Intensive Care Unit; <sup>a</sup> adjusted for age group, sex, initial hospitalization, and initial symptom severity.*

**Table S7:** Sensitivity analysis of relative health status, fatigue, dyspnea, mental health, and health-related quality of life in study participants at six to eight months after SARS-CoV-2 infection, stratified into time periods of limited and increased testing for SARS-CoV-2, as well as with limited and increased awareness of post-COVID-19 syndrome.

Variable	Test timing (25 Jun 2020)		Awareness (09 Nov 2020)		Overall, N=431
	Limited testing, N=313	Increased testing, N=117	Lower awareness of post-COVID syndrome, N=129	Increased awareness of post-COVID syndrome, N=302	
<b>Recovery</b>					
Recovered to normal health status	237 (75.7%)	82 (70.1%)	102 (79.1%)	218 (72.2%)	320 (74.2%)
Not recovered to normal health status	76 (24.3%)	35 (29.9%)	27 (20.9%)	84 (27.8%)	111 (25.8%)
<b>Self-reported symptoms</b>					
No new or ongoing symptoms	235 (75.1%)	89 (76.1%)	95 (73.6%)	230 (76.2%)	325 (75.4%)
Any new or ongoing symptoms	78 (24.9%)	28 (23.9%)	34 (26.4%)	72 (23.8%)	106 (24.6%)
<b>Recovery and symptoms</b>					
Recovered and symptom-free	197 (62.9%)	67 (57.3%)	83 (64.3%)	182 (60.3%)	265 (61.5%)
Not recovered or experiencing symptoms	116 (37.1%)	50 (42.7%)	46 (35.7%)	120 (39.7%)	166 (38.5%)
<b>Fatigue (measured by FAS)</b>					
No fatigue	144 (46.8%)	49 (41.9%)	69 (54.3%)	124 (41.5%)	193 (45.3%)
Fatigue	164 (53.2%)	68 (58.1%)	58 (45.7%)	175 (58.5%)	233 (54.7%)
Missing	5	0	2	3	5
<b>Dyspnea (measured by mMRC scale)</b>					
mMRC grade 0	212 (74.4%)	86 (78.9%)	87 (73.1%)	212 (76.8%)	299 (75.7%)
mMRC grade 1	59 (20.7%)	22 (20.2%)	29 (24.4%)	52 (18.8%)	81 (20.5%)
mMRC grade ≥2	14 (4.9%)	1 (0.9%)	3 (2.5%)	12 (4.3%)	15 (3.8%)
Missing	28	8	10	26	36
<b>Depression (measured by DASS-21)</b>					
No depression	233 (75.2%)	83 (70.9%)	99 (77.3%)	218 (72.7%)	317 (74.1%)
Mild to moderate depression	59 (19.0%)	26 (22.2%)	18 (14.1%)	67 (22.3%)	85 (19.9%)
Severe to very severe depression	18 (5.8%)	8 (6.8%)	11 (8.6%)	15 (5.0%)	26 (6.1%)
Missing	3	0	1	2	3
<b>Anxiety (measured by DASS-21)</b>					
No anxiety	213 (69.2%)	77 (65.8%)	93 (73.2%)	198 (66.2%)	291 (68.3%)
Mild to moderate anxiety	68 (22.1%)	35 (29.9%)	26 (20.5%)	77 (25.8%)	103 (24.2%)
Severe to very severe anxiety	27 (8.8%)	5 (4.3%)	8 (6.3%)	24 (8.0%)	32 (7.5%)
Missing	5	0	2	3	5
<b>Stress (measured by DASS-21)</b>					

No stress	263 (85.7%)	93 (79.5%)	112 (88.9%)	245 (81.9%)	357 (84.0%)
Mild to moderate stress	33 (10.7%)	18 (15.4%)	11 (8.7%)	40 (13.4%)	51 (12.0%)
Severe to very severe stress	11 (3.6%)	6 (5.1%)	3 (2.4%)	14 (4.7%)	17 (4.0%)
Missing	6	0	3	3	6
<b>EQ-5D mobility</b>					
No mobility problems	276 (88.7%)	104 (88.9%)	115 (89.1%)	266 (88.7%)	381 (88.8%)
Mobility problems	35 (11.3%)	13 (11.1%)	14 (10.9%)	34 (11.3%)	48 (11.2%)
Missing	2	0	0	2	2
<b>EQ-5D self care</b>					
No problems with self-care	310 (99.4%)	117 (100.0%)	129 (100.0%)	299 (99.3%)	428 (99.5%)
Problems with self-care	2 (0.6%)	0 (0.0%)	0 (0.0%)	2 (0.7%)	2 (0.5%)
Missing	1	0	0	1	1
<b>EQ-5D usual activities</b>					
No problems during usual activities	278 (89.1%)	106 (90.6%)	117 (90.7%)	268 (89.0%)	385 (89.5%)
Problems during usual activities	34 (10.9%)	11 (9.4%)	12 (9.3%)	33 (11.0%)	45 (10.5%)
Missing	1	0	0	1	1
<b>EQ-5D pain &amp; discomfort</b>					
No pain or discomfort present	192 (61.7%)	84 (72.4%)	84 (65.1%)	193 (64.5%)	277 (64.7%)
Pain or discomfort present	119 (38.3%)	32 (27.6%)	45 (34.9%)	106 (35.5%)	151 (35.3%)
Missing	2	1	0	3	3
<b>EQ-5D anxiety &amp; depression</b>					
No anxiety or depression present	222 (71.2%)	75 (64.1%)	85 (65.9%)	212 (70.4%)	297 (69.1%)
Anxiety or depression present	90 (28.8%)	42 (35.9%)	44 (34.1%)	89 (29.6%)	133 (30.9%)
Missing	1	0	0	1	1
<b>EQ-5D-5L index score</b>					
Median (IQR)	0.89 (0.84 to 1.00)	0.89 (0.85 to 1.00)	0.89 (0.83 to 1.00)	0.89 (0.85 to 1.00)	0.89 (0.85 to 1.00)
Range	0.07 to 1.00	0.41 to 1.00	0.44 to 1.00	0.07 to 1.00	0.07 to 1.00
Missing	3	1	0	4	4
<b>EQ VAS</b>					
Median (IQR)	85 (77 to 90)	85 (77 to 90)	85 (77 to 90)	85 (77 to 90)	85 (77 to 90)
Range	20 to 100	40 to 100	50 to 100	20 to 100	20 to 100
Missing	8	2	5	5	10

*Legend: FAS = Fatigue Assessment Scale, mMRC = modified Medical Research Council, DASS-21 = Depression, Anxiety and Stress Score (21 items), EQ = EuroQol, VAS = Visual Analogue Scale, IQR = Interquartile Range.*

**Table S8:** Comparison of population characteristics of participants of the Zurich SARS-CoV-2 Cohort study and individuals not participating in the study.

Variable	Participants included in analysis <sup>a,b</sup> , N=431	Enrolled Participants <sup>b,c</sup> , N=442	Nonparticipants <sup>c</sup> , N=858
<b>Age group (years)</b>			
18-39	164 (38.1%)	170 (38.4%)	325 (37.9%)
40-64	205 (47.6%)	208 (47.1%)	352 (41.0%)
≥65	62 (14.4%)	64 (14.5%)	181 (21.1%)
<b>Sex</b>			
Female	214 (49.7%)	218 (49.3%)	415 (48.4%)
Male	217 (50.3%)	224 (50.7%)	440 (51.3%)
Missing	0	0	3 (0.3%)
<b>Initial symptoms</b>			
Symptomatic	385 (89.3%)	370 (83.7%)	692 (80.7%)
Asymptomatic	46 (10.7%)	8 (1.8%)	36 (4.2%)
Missing	0	64 (14.5%)	130 (15.1%)
<b>Time from symptom onset to diagnosis</b>			
Median (IQR)	-	2 (1 to 5)	2 (1 to 5)
<b>Hospitalization</b>	81 (18.8%)	58 (13.2%)	205 (23.9%)

**Legend:** <sup>a</sup> Data presented refers to that collected in the Zurich SARS-CoV-2 Cohort study. <sup>b</sup> Data presented refers to that recorded in contact tracing files within the Department of Health. <sup>c</sup> Includes all participants who consented to participate in the Zurich SARS-CoV-2 Cohort study (i.e., including 6 individuals with suspected reinfection and 5 individuals that never filled a questionnaire). Time from symptom onset to diagnosis was not retrospectively elicited in our study.